Trials / Completed
CompletedNCT00300339
Mixed Antagonist of Serotonin for Claudication Optimal Therapy
Double-Blind, Double-Dummy, Randomized, Parallel Group Trial of SL650472 (Three Dose Regimens Versus Placebo and Cilostazol), for 24-Week Improvement of Walking Distance in Patients With Stage II Peripheral Arterial Disease Who Benefit From Optimal Prevention Strategy Including Clopidogrel
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 599 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
To investigate in patients suffering from intermittent claudication due to Fontaine stage II PAD whether a 24-week treatment by SL650472 OD on top of clopidogrel may result in an improvement of walking capacity, by comparing three doses of SL650472 to placebo, and to calibrate such effect versus cilostazol
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SL650472, Clopidogrel |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2006-03-08
- Last updated
- 2008-12-19
Locations
9 sites across 9 countries: United States, Belgium, Canada, Czechia, Germany, Mexico, Russia, Sweden, Ukraine
Source: ClinicalTrials.gov record NCT00300339. Inclusion in this directory is not an endorsement.